ArticleFrontiers in nutrition2022
A novel bacteriocin isolated from
Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Chitosan-Based Composite Film Containing Cell-Free Supernatant ofGels (Basel, Switzerland) · 2026Article
- Culture filtrates of lactic acid bacteria promote the growth and enhance the resistance of tomato seedlings to Ralstonia solanacearum.BMC plant biology · 2026Article
- Current Status and Future Challenges in the Use of Bacteriocins to Modulate Ruminant Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Lactic Acid Bacteria as the Green and Safe Food Preservatives: Their Mechanisms, Applications and Prospects.Foods (Basel, Switzerland) · 2026Review
- A Small-Molecular-Weight Bacteriocin-like Inhibitory Substance (BLIS) UI-11 Produced byVeterinary sciences · 2025Article
- Inhibitory efficacy, production dynamics, and characterization of postbiotics of lactic acid bacteria.BMC microbiology · 2025Article
- Lactiplantibacillus Plantarum as a Complementary Approach for Diabetes Treatment and Management.Current nutrition reports · 2025Review
- Leuconostoc lactis strain APC 3969 produces a new variant of cyclic bacteriocin leucocyclicin Q and displays potent anti-Clostridium perfringens activity.Scientific reports · 2025Article
- Article
- Bactofencin YH, a novel bacteriocin with high inhibitory activity against clinical Streptococcus species.World journal of microbiology & biotechnology · 2024Article
- Biosynthesis of bacteriocin BacZY05-silver nanoconjugates and evaluation of their antibacterial properties.World journal of microbiology & biotechnology · 2024Article
- Enhanced production of bacteriocin by3 Biotech · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, screening bacteriocin-producing strains from 2,000 plant-derived strains by agar well diffusion method was conducted. The corresponding produced bacteriocin was purified and identified by Sephadex gel chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Meanwhile, the biological characteristics of bacteriocin were investigated. The targeted strain W3-2 was obtained and identified as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.